Therefore, IDO inhibitors (IDOi) can overcome the immunosuppressive TME and promote activation of T cells.[12] Notably, the combination of the IDOi and CAR‐T cells showed improved tumor control over lymphoma,[13] which suggested that IDOi can promote activation of CAR‐T cells. This evidence concerns the gene IDO1 and neoplasm.